---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-270286"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:00:39.879706+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eledon Phase 2 BESTOW trial: tegoprubart eGFR 69 vs tacrolimus 66, primary endpoint not met but safety superior

## Summary
- Primary efficacy endpoint (eGFR at 12 months) did not reach statistical significance: 69 vs 66 mL/min/1.73 m².
- New-onset diabetes 1/47 on tegoprubart vs ~1/6 on tacrolimus; tremor 1.6% vs 25.0%; delayed graft function 14.3% vs 25.0%.
- Efficacy failure composite (death, graft loss, BPAR) was 22% tegoprubart vs 17% tacrolimus, meeting non-inferiority margin.
- Cash, equivalents, and short-term investments approximately $93.4M as of Sept 30, 2025, expected to fund operations to late 2026.
- Company plans to advance tegoprubart into Phase 3 after regulatory discussions on study design and data requirements.

## SEC filing metadata
- accession: 0001193125-25-270286
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000119312525270286/0001193125-25-270286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000119312525270286/eldn-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-270286
- JSON: https://secwatch.observer/filing/0001193125-25-270286.json
- Plain text: https://secwatch.observer/filing/0001193125-25-270286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.